Cost–effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. (April 2015)

• Record Type: Journal Article
• Authors: Cangelosi, Michael J; Ortendahl, Jesse D; Meckley, Lisa M; Bentley, Tanya GK; Anene, Ayanna M; Shriner, Kelly M; Fox, John
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 15:Number 2(2015)
• Page Start: 357
• Page End: 364
• Publication Date: 2015-04
• Subjects: Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1586/14737167.2015.978292
• Languages: English
• ISSNs: 1473-7167

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Objectives: We examined the cost–effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. Study design: We conducted a model-based cost–effectiveness analysis assessing 5-year healthcare utilization, patient quality of life and adverse events. Methods: We utilized Markov modeling to estimate the costs and quality-of-life impact of BT compared with high-dose combination therapy among poorly controlled, severe, persistent asthma patients: those requiring high-dose combination therapy and having experienced an asthma exacerbation-related ER visit in the past year. Results: The cost–effectiveness of BT was US$5495 per quality-adjusted life year; and approximately 22% of sensitivity analysis iterations estimated BT to reduce costs and increase quality of life. Conclusions: BT is a cost–effective treatment option for patients with poorly controlled, severe, persistent asthma.</p> </abstract>